Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880713 | 0.89 | OPRK1 (0.47) | OPRK1 | |
| SCHEMBL18398582 | 0.84 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL4919152 | 0.82 | OPRK1 (0.44) | OPRK1 | |
| SCHEMBL20872624 | 0.81 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL18616879 | 0.80 | MMP2 (0.49) | OPRK1 | |
| SCHEMBL29988045 | 0.79 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL20889335 | 0.79 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL29517846 | 0.79 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL1886755 | 0.79 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL30989841 | 0.79 | OPRK1 (0.50) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-120004861-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115160311-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115160311-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-4058015-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115066240-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021096948-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | OPRK1 1645/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | OPRK1 4547/4885 |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | OPRK1 1645/4885 |
| US-10357484-B2 | Heterocyclic compound | HDAC1, HDAC11, HDAC5 | OPRK1 3608/4885 |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | OPRK1 1645/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | OPRK1 4547/4885 |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC11, HDAC5 | OPRK1 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.